Nuvalent (NASDAQ:NUVL) specializes in creating precisely targeted therapies for patients with cancer. Dedicated to advancing the treatment of cancer, their operations focus on developing a robust portfolio of innovative drugs designed to address the limitations of existing therapies. Their projects aim to tackle molecularly defined cancers by discovering and developing chemically advanced, selective small molecules that are intended to overcome drug resistance and improve patient outcomes. The objective at Nuvalent is to push the boundaries of cancer treatment, ensuring more effective and safer therapeutic options are available to those in need. Through meticulous research and development efforts, Nuvalent is committed to fulfilling unmet medical needs in the oncology space.